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Of all patients having an acute myocardial infarction (AMI), 25-35% will die of sud-
den cardiac death (SCD) due to ventricular fibrillation (VF) before seeking medical 
attention. For those who reach the hospital, prognosis is considerably better and has 
improved over the years. Reperfusion therapy, which is superior with primary percu-
taneous coronary intervention (PCI) versus thrombolysis, has made the difference. 
There is currently overwhelming evidence in favor of an expanded role and use of 
primary PCI in an attempt to reduce the risk of SCD early and late after an AMI. In-
hospital SCD due to acute (<48 hours) ventricular tachyarrhythmias is manageable, 
with either preventive measures or electrical cardioversion; these arrhythmias do not 
portend an adverse late outcome. secondary prevention of SCD in the early post-
AMI period is accomplished via an implantable cardioverter defibrillator (ICD) for 
sustained ventricular arrhythmias emerging >48 hours after an AMI, not due to re-
versible or correctable causes. However, the major challenge remains that of primary 
prevention of SCD between the 48-hour period and the first 40 days post-AMI for 
patients who have low left ventricular ejection fraction (LVEF) and are not candidates 
for an ICD according to current guidelines. Two ICD trials (DINAMIT and IRIS) 
have shown no benefit of ICD in this early period. Two recent documents may provide 
direction as to how to bridge this early gap. The first relates to the “appropriate use 
criteria for ICDs and cardiac resynchronization therapy (CRT)”, and the second is 
an “expert consensus statement on the use of ICD therapy in patients who are not 
included or not well represented in clinical trials”.
Ventricular arrhythmias are common during the early hours after acute myocardial 
infarction (AMI).1,2 The mechanisms for these arrhythmias are multifactorial and 
include ongoing ischemia, hemodynamic and electrolyte abnormalities, reentry, and 
enhanced automaticity. Of all patients having an AMI, 25-35% will die of ventricular 
fibrillation (VF) before seeking medical attention. For those who reach the hospital, 
prognosis is considerably better and has improved over the years. 
The long-term prognostic significance of early (<48 hours) VF or sustained ven-
tricular tachycardia (VT) in patients with AMI remains dubious. In patients with AMI, 
early VF/VT may identify those at increased risk for 30-day mortality (22% vs 5%) as 
compared to those without VF/ VT. Angiotensin converting enzyme (ACE) inhibitors/
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angiotensin receptor blockers (ARBs) may reduce the 30-day 
mortality in these patients.1 Other studies have confirmed 
that beta-blocker therapy, given in the first 24 hours after AMI 
in patients with early sustained VF/VT, was associated with 
reduced early mortality without worsening heart failure 
Over the years, in-hospital mortality rate (MR) of AMI fell 
from 11.2% in 1990 to 9.4% in 1999. Most of the decline among 
patients with AMI is a consequence of reperfusion therapy via 
fibrinolysis or primary percutaneous coronary intervention 
(PCI), with primary PCI being superior to fibrinolysis.3-5 Analy-
sis by the National Registry of MI indicated that in-hospital 
MR was 5.7% among those receiving reperfusion therapy, as 
compared with 14.8% among those who were eligible for but 
did not receive such therapy.4 In a meta-analysis [23 studies 
of primary PCI (3872 patients) and fibrinolytic therapy (3867 
patients)],3 MR at 4-6 weeks after treatment was significantly 
lower among those who underwent primary PCI (7% vs 9%).
Treatment of in-hospital sustained ventricular arrhythmias 
is usually easy and effective by applying immediate defibril-
lation or cardioversion for VF or pulseless sustained VT, 
respectively, and antiarrhythmic drug therapy according with 
the 2010 ACLS guidelines for sustained VT with a pulse.6 The 
prophylactic use of lidocaine is not recommended. Prevention 
of in-hospital sudden cardiac death (SCD) due to VT/VF is 
directed toward correction of electrolyte and acid/base abnor-
malities, optimization of myocardial perfusion, eradication of 
ongoing ischemia, and treatment of associated complications 
such as heart failure or shock. Premature ventricular contrac-
tions (PVCs), nonsustained VT not associated with hemody-
namic compromise, and accelerated idioventricular rhythms 
(AIVRs) that emerge after reperfusion are not indicative of 
increased SCD risk and do not require specific therapy in the 
acute phase of AMI.1
Thus, inhospital SCD due to ventricular tachyarrhythmias 
is manageable. The major mechanism of early death in patients 
who die the day of or the day following primary angioplasty 
(day 0 or 1) for AMI is usually pump failure (83%) and not 
ventricular tachyarrhythmias. Similarly, the major mechanism 
of death in patients who die within 30 days after primary an-
gioplasty for AMI is still pump failure (61%),7 and may be the 
reason why the implantable cardioverter defibrillator (ICD) 
has not been shown to be effective in reducing MR. However, 
there is still a good percentage of patients afflicted by SCD 
during this early period. 
Decreased left ventricular (LV) function is a strong pre-
dictor of mortality. Although current guidelines recommend 
prophylactic ICD implantation after AMI and a depressed LV 
ejection fraction (LVEF) for 1 month, the prognoses of these 
patients may be better than those observed in randomized 
trials of ICDs (1-year mortality 6.8-19%), particularly because 
reperfusion treatment has improved, and the use of life-saving 
drugs is higher.1 According to a prospective, observational 
study, assessing 1-year mortality in patients with depressed 
LVEFs after primary PCI, among patients who were alive >30 
days after primary PCI but remained with low (<30%) LVEFs, 
overall 1-year mortality was as low as 5.8% compared with 
earlier times when primary PCI was not available.8 However, 
still SCD remained the most common cause of death (40%). 
Patients who died more often had multivessel disease and a 
higher incidence of recurrent myocardial infarction within 1 
year. Thus, there is still an important role for ICD therapy in 
these patients.
Current guidelines (Acc/AHA guidelines 2013 / Esc 
guidelines 2012) indicate:1,2 
	 ●	ICD therapy is indicated before discharge for secondary 
prevention in patients who develop sustained VT/VF >48 
hours after AMI, provided the arrhythmia is not due to 
transient or reversible ischemia, reinfarction, or metabolic 
abnormalities. (Class I, LOE: B)
	 ●	For other at-risk patients, particularly those with sig-
nificantly reduced LVEF, candidacy for ICD therapy for 
primary prevention of SCD should be reassessed at 40 days 
after discharge
	 ●	For primary prevention, patients with an initially reduced 
LVEF who are possible candidates for ICD therapy should 
undergo reevaluation of LVEF ≥40 days after discharge. 
(Class I, LOE: B)
	 ●	The utility of a wearable cardioverter-defibrillator in high-
risk patients during the first 4-6 weeks after AMI is under 
investigation
	 ●	Evaluation of the need for a primary preventive ICD im-
plantation may, in some cases, be postponed until 3 months 
after revascularization procedures, to allow adequate time 
for recovery of LV function.
In general, patients who undergo coronary revasculariza-
tion after AMI have a significantly lower rate of SCD than do 
patients who do not undergo revascularization.9 
secondary prevention of SCD in the early post-AMI pe-
riod is accomplished via an implantable cardioverter defibrilla-
tor (ICD) for sustained ventricular arrhythmias emerging >48 
hours after an AMI, not due to reversible or correctable causes. 
However, the major challenge remains that of primary 
prevention of SCD between the 48-hour period and the first 
40 days post-AMI for patients who have low LVEF and are 
not candidates for an ICD according to current guidelines. 
These guidelines rely on the results from mainly 2 studies:10,11 
	 ●	The DINAMIt study10 assessed ICD use in 674 patients 
within 4-40 days after AMI who were receiving optimal 
medical therapy, had LVEF ≤35% (mean 28%) and mark-
ers of autonomic dysfunction (low heart rate variability-
HRV). Although low LVEF and low HRV identify patients 
with increased mortality risk, the trial did not identify any 
benefits from the use of ICD. 
	 ●	The IrIs study showed similar results.11 The study in-
cluded 900 high-risk patients within 1 month of an AMI 
with LVEF <40% (mean LVEF 35%). Although the ICD 
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group had a significant decrease in arrhythmic MR, this 
was offset by an increase in nonarrhythmic death, similar 
to DINAMIT.
However, one should note that only 27% of patients were 
treated with primary PCI in the DINAMIT trial; a larger per-
centage of patients received primary PCI (72%) in the IRIS 
study. Despite the recommendations of the guidelines to avoid 
an ICD during the first 30-40 days post-AMI, the mortality 
risk remains high. According with the VALIANT trial results, 
mortality is highest early after an AMI, especially during the 
first one month and particularly for those with LVEF <30%.12 
An electrophysiology (EP)-guided approach with targeted 
ICD implantation was proposed by an Australian study for 
patients after AMI treated with primary PCI. Early ICD 
implantation was limited to patients with inducible VT.13 The 
conclusion of this study was that use of LVEF assessment 
and EP study for risk stratification soon after primary PCI for 
AMI, with ICD implantation limited to those with inducible 
VT, produces a uniformly low mortality on follow-up, includ-
ing those patients with low LVEF. N.B.: in contrast to prior 
studies in patients with recent AMI, in which a minority of 
patients had PCI, this study had 95% of patients revascular-
ized with primary PCI.
There is currently overwhelming evidence in favor of an 
expanded role and use of primary PcI in an attempt to reduce 
the risk of SCD early and late after AMI. Indeed, although 
LVEF is a predictor of increased risk for SCD, there is a low 
incidence of SCD in post-AMI survivors in the primary PCI 
era.3-5,7-9,14
In order to bridge the gap of the first 40 days after AMI 
for patients with low LVEF, the EPHESuS trial established 
the benefit of an aldosterone antagonist, eplerenone, added to 
optimal medical therapy in eligible patients; results indicated 
that earlier initiation of eplerenone (<7 days) significantly 
reduced the rates of all-cause mortality, SCD, and cardiovas-
cular mortality/hospitalization.15
To further cover the gap of guideline direction regarding 
bridging for these 40 days after STEMI for patients with low 
LVEF, two documents have recently been published to guide 
us through this period of high risk:
According with the ACCF/HRS/AHA/ASE/HFSA/SCAI/
SCCT/SCMR 2013 appropriate use criteria for ICDs and CRT, 
in patients with recent AMI (≤40 days) and low LVEF (≤40%), 
who develop nonsustained VT >4 days post-AMI, whether 
revascularized or not, an EP study may be used to guide 
therapy. Those with inducible VT receive an ICD early post-
AMI without having to wait for those 40 days (Heart Rhythm 
2013; 10. http://dx.doi.org/10.1016/j.hrthm.2013.01.008).16 
For those amenable to revascularization, the EP study should 
be performed after the revascularization procedure.
According to another very recent document “in patients 
who, within 40 days of an AMI, require nonelective permanent 
pacing, who also would meet primary prevention criteria 
for implantation of an ICD, and recovery of LV function 
is uncertain or not expected, implantation of an ICD with 
appropriately selected pacing capabilities is recommended” 
(HRS/ACC/AHA Expert Consensus Statement on the use 
of Implantable Cardioverter-Defibrillator Therapy in Patients 
Who Are Not Included or Not Well Represented in Clinical 
Trials).17 Also, “In patients who, within 40 days of an AMI, 
present with syncope that is thought to be due to ventricular 
tachyarrhythmia (by clinical history, documented nonsustained 
VT, or EP study), implantation of an ICD can be useful”.
Similarly, according with the same document, “in patients 
within 90 days of revascularization who require nonelective 
permanent pacing, who would also meet primary prevention 
criteria for implantation of an ICD, and in whom recovery 
of LV function is uncertain or not expected, implantation 
of an ICD with appropriately selected pacing capabilities 
is recommended”. Also, “in patients who within 90 days of 
revascularization present with syncope that is thought to be 
due to ventricular tachyarrhythmia (by clinical history or 
documented nonsustained VT, or EP study), implantation of 
an ICD can be useful”.17
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